Novel Helicobacter pylori therapeutic targets: the unusual suspects

Megan J Duckworth1, Arinze S Okoli, George L Mendz

  • 1School of Medicine, Sydney, The University of Notre Dame Australia, 160 Oxford Street, Darlinghurst, NSW 2010, Australia. meganjaned@gmail.com

Insights

Discovering new anti-Helicobacter therapies involves identifying therapeutic targets in Helicobacter pylori. Despite extensive research into bacterial genes, few novel treatments have emerged.

Area of Science:

  • Microbiology
  • Drug Discovery
  • Genetics

Background:

  • Helicobacter pylori is a significant human pathogen.
  • Current anti-Helicobacter therapies face challenges with resistance and efficacy.
  • Identifying novel therapeutic targets is crucial for developing new treatments.

Purpose of the Study:

  • To review and summarize the research efforts in identifying potential therapeutic targets within Helicobacter pylori.
  • To categorize and evaluate the identified genes as potential targets for anti-H. pylori therapies.

Main Methods:

  • Comprehensive literature review of studies focused on Helicobacter pylori gene discovery for therapeutic intervention.
  • Categorization of identified potential targets based on the extent of their characterization.
  • Evaluation of key candidate genes within each category.

Main Results:

  • A substantial number of Helicobacter pylori genes have been investigated as potential therapeutic targets.
  • Identified targets include genes involved in metabolism, growth, motility, and colonization.
  • Candidates were classified into three tiers based on research depth.

Conclusions:

  • Extensive research into H. pylori targets has significantly advanced understanding of its physiology, genetics, and host interactions.
  • Despite considerable effort, the development of new anti-Helicobacter therapies based on these targets has been limited.

Related Concept Videos

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Peptic Ulcer Disease II: Pathophysiology01:24

Peptic Ulcer Disease II: Pathophysiology

Peptic ulcer disease develops when protective mechanisms of the gastrointestinal mucosa are overwhelmed by harmful factors, leading to localized erosions in the stomach or proximal duodenum. The main causes are Helicobacter pylori infection and chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs).Helicobacter pylori–Induced InjuryBacterial Adaptation and Colonization:H. pylori is a spiral, Gram-negative bacterium adapted to the acidic stomach. and transmitted through oral-oral or...
Peptic Ulcer Disease II: Pathophysiology01:28

Peptic Ulcer Disease II: Pathophysiology

Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Gastritis II: Pathophysiology01:26

Gastritis II: Pathophysiology

The pathophysiology of gastritis begins with the colonization of the stomach lining by Helicobacter pylori (H. pylori). This bacterium spreads mainly via the oral-oral route through saliva or shared utensils, and can also be transmitted in overcrowded or unhygienic environments through contaminated water, despite its brief survival outside the body.ColonizationOnce ingested, H. pylori enters the stomach and begins colonization by navigating through the mucus layer lining the stomach wall. It...
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...